ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023 ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...

European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease Cholesterol Transport Mediator™ VAR 200 is in development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including...

ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...